Using Erythropoietin, a critical hormone involved in erythropoiesis, as a model protein, this case study represents a significant step in understanding the glycans presented by Future Fields’ fly-based protein production platform.
This case study covers:
- Glycopeptide Analysis
- Bioactivity Data
- Glycan Comparisons
Scientists seeking a protein expression partner to produce their protein of interest can rest assured knowing that the Drosophila melanogaster whole-insect approach yields glycosylated, functionally bioactive recombinant proteins.
No matter how challenging your protein of interest is, our team of dedicated scientists and engineers is here to help you succeed.
The Advantages of the EntoEngine™
Targeted gene expression and controlled gene regulation
Cost-effective scalability and operational efficiency
Ability to express difficult-to-express proteins
Delivery of proteins with post-translational modification (PTMs)
Case study at a glance
N-glycosylated purified EntoEngine-EPO appeared at a MW of ~25 kDa. PNGase treated EPO to remove N-linked glycans shifted to a lower MW of ~20 kDa while PNGase enzyme appeared at ~36 kDa.
Dose-dependent proliferation of TF-1 cells induced by multiple lots of the EntoEngine-derived EPO by alamarBlue assay analysis with EC₅₀ ≤0.26 ng/mL.
